A Study of Durvalumab (MEDI4736) in Esophageal Cancer
NCT02639065
·
clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
39
Enrollment
OTHER
Sponsor class
Conditions
Esophageal Cancer
Interventions
DRUG:
Durvalumab
Sponsor
Shadia Jalal, MD
Collaborators
[object Object]
[object Object]
[object Object]